BATON ROUGE, LA (WAFB) - LSU Pennington Biomedical Research Center is looking for preteens and teens with type 2 diabetes to participate in a study on an investigation drug. Parents or guardians must complete the online screening.
This TDR14311 research study will assess an investigational drug (Lixisenatide) for the treatment of type 2 diabetes in adolescents.
The rate of type 2 diabetes in adolescents continues to rise. Currently, metformin is the only oral drug recommended as the initial medical treatment for type 2 diabetes in adolescents; however, metformin is not suitable for all adolescents. Therefore, there is a need for more treatment options for adolescents with type 2 diabetes.
The drug Lixisenatide is approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with type 2 diabetes. Pennington Biomedical is one of the research sites working to examine the drug's effectiveness in an adolescent population (10-17 years old).
The study will last approximately 10 weeks overall with 6 weeks of taking the study medication.
NUMBER OF VISITS
- 2 screening visits
- 4 treatment visits
- 1 end of Study visit
- Health measurements (blood pressure, pulse, height, weight, etc.)
- Physical Examination
- ECG test to determine heart health
- Blood tests
- Be 10 to 17 years old at the time of screening
- Diagnosed with type 2 diabetes
- Have a BMI greater than the 85 percentile for age and gender (calculate your BMI) http://www.pbrc.edu/clinical-trials/bmi/
- Not be pregnant
Compensation of up to $1433 is offered for completion of this study.